Blurbs

Affimed (AFMD) Initiated with a Buy at Leerink Partners

Affimed (AFMDResearch Report) received a Buy rating from Leerink Partners analyst Daina Graybosch yesterday. The company’s shares closed last Monday at $4.55, close to its 52-week low of $3.59.

According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of -15.6% and a 31.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Affimed with a $10.00 average price target, representing a 104.3% upside. In a report issued on March 30, Piper Sandler also initiated coverage with a Buy rating on the stock with a $7.00 price target.

See the top stocks recommended by analysts >>

Affimed’s market cap is currently $527M and has a P/E ratio of -7.90.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Read More on AFMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos